

25 April 2023

Diaceutics PLC
("Diaceutics" or "the Company")

Notice of AGM and Posting of Annual Report

[Diaceutics PLC](#), (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces that it has today posted its Annual Report for the year ended 31 December 2022 to shareholders together with the Notice of the 2023 Annual General Meeting ("AGM").

The Company will hold its AGM on Thursday 18 May 2023 at 10:30am at First Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park, Belfast, County Antrim BT9 6GW.

The Annual Report and Notice of AGM are now available on the Company's website at www.diaceutics.com.

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)
Ben Maddison
Nick Harland
Nick Adams
Kate Hanshaw

Tel: +44 (0)20 7710 7600

Alma PR
Caroline Forde
Kieran Breheny
Matthew Young
Kinvara Verdon

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOABLGDSDDGXU

